Penumbra price target raised to $286 from $246 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on Penumbra to $286 from $246 and keeps a Buy rating on the shares. The analyst said management remains very confident in its newest launches, Lightning Flash (for venous – PE, DVT) and Lightning Bolt (for arterial), citing positive physician feedback and stating that Flash to date is the most successful launch in the company’s history.